LGALS3 and Parkinson disease: In Parkinson’s disease (PD), extracellular α-synuclein-aggregate-induced inflammation can be reduced by Gal-3 inhibition, which suggests therapeutic potential for Gal-3 (Boza-Serrano et al., 2014).